Please enable JavaScript to continue using this application.

Compare $NKTX vs $VYGR | Chartloom

Compare

$NKTX vs $VYGR

Nkarta Inc · Voyager Therapeutics Inc

NKTX

Nkarta Inc

VYGR

Voyager Therapeutics Inc

Compare $NKTX vs $VYGR

Comparing Nkarta Inc and Voyager Therapeutics Inc

NKTXNkarta Inc

VYGRVoyager Therapeutics Inc

NKTXNkarta Inc

Market cap

$161M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

20.3%

52W performance

7.7%

FCF yield

-58.3%

VYGRVoyager Therapeutics Inc

Market cap

$148M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

5.33x

Rev growth (TTM)

-19.1%

YTD performance

-39.2%

52W performance

-53.6%

FCF yield

-82.0%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

NKTX

VYGR

Detailed metrics comparison

NKTX

Nkarta Inc

VYGR

Voyager Therapeutics Inc

Market Cap

NKTX$161M

VYGR$148M

Enterprise Value

NKTX$136M

VYGR$112M

Price

NKTX$2.25

VYGR$2.45

P/E Ratio

NKTXN/A

VYGRN/A

P/S Ratio

NKTX0.00x

VYGR4.30x

EV/Sales

NKTX0.00x

VYGR3.26x

EV/EBITDA

NKTX0.00x

VYGR8.61x

P/B Ratio

NKTX0.74x

VYGR1.01x

P/FCF Ratio

NKTXN/A

VYGRN/A

EV/FCF

NKTX-1.45x

VYGR-0.92x

PEG Ratio

NKTXN/A

VYGRN/A

Forward P/E (NTM)

NKTXN/A

VYGRN/A

Forward P/S (NTM)

NKTXN/A

VYGR5.33x

Revenue (TTM)

NKTX$0

VYGR$34M

Revenue Growth (YoY)

NKTXN/A

VYGR-19.1%

Forward Rev Growth

NKTX2561.2%

VYGR129.7%

Gross Margin (TTM)

NKTX0.0%

VYGR0.0%

Operating Margin (TTM)

NKTX0.0%

VYGR0.0%

EBITDA Margin (TTM)

NKTX0.0%

VYGR-329.0%

Net Margin (TTM)

NKTX0.0%

VYGR-312.6%

FCF Margin (TTM)

NKTXN/A

VYGR-352.4%

Net Income (TTM)

NKTX$-117M

VYGR$-108M

FCF (TTM)

NKTX$-94M

VYGR$-121M

EPS (TTM)

NKTX-$1.57

VYGR-$1.78

ROE (TTM)

NKTX-3964.0%

VYGR-5792.0%

ROA (TTM)

NKTX-3045.0%

VYGR-4500.0%

ROIC (TTM)

NKTX-3964.0%

VYGR-5792.0%

Cash

NKTX$25M

VYGR$36M

Debt

NKTX$0

VYGR$0

Net Cash/Debt

NKTX$25M

VYGR$36M

Current Ratio (TTM)

NKTX7.98x

VYGR7.51x

Quick Ratio (TTM)

NKTX7.76x

VYGR7.16x

Debt/Equity (TTM)

NKTX0.00x

VYGR0.00x

Debt/Assets (TTM)

NKTX0.0%

VYGR0.0%

Interest Coverage (TTM)

NKTXN/A

VYGRN/A

Net Debt/EBITDA (TTM)

NKTX0.00x

VYGR0.00x

Beta

NKTX1.19

VYGR1.11

52W Performance

NKTX7.7%

VYGR-53.6%

YTD Performance

NKTX20.3%

VYGR-39.2%

% from 52W High

NKTX-39.5%

VYGR-55.9%

% from 52W Low

NKTX32.4%

VYGR5.2%

Asset Turnover (TTM)

NKTX0.00x

VYGR0.14x

FCF Yield (TTM)

NKTX-58.3%

VYGR-82.0%

Earnings Yield (TTM)

NKTX-72.9%

VYGR-72.8%

Dividend Yield (TTM)

NKTXN/A

VYGRN/A

Rule of 40

NKTX0.0

VYGR-371.4

EV/GP/RG

NKTXN/A

VYGRN/A

Ticker research

View NKTX research View VYGR research

Metric	NKTX Nkarta Inc	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$161M	$148M
Enterprise Value	$136M	$112M
Price	$2.25	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	4.30x
EV/Sales	0.00x	3.26x
EV/EBITDA	0.00x	8.61x
P/B Ratio	0.74x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.45x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.33x
Revenue & Growth
Revenue (TTM)	$0	$34M
Revenue Growth (YoY)	N/A	-19.1%
Forward Rev Growth	2561.2%	129.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-329.0%
Net Margin (TTM)	0.0%	-312.6%
FCF Margin (TTM)	N/A	-352.4%
Net Income (TTM)	$-117M	$-108M
FCF (TTM)	$-94M	$-121M
EPS (TTM)	-$1.57	-$1.78
ROE (TTM)	-3964.0%	-5792.0%
ROA (TTM)	-3045.0%	-4500.0%
ROIC (TTM)	-3964.0%	-5792.0%
Financial Health
Cash	$25M	$36M
Debt	$0	$0
Net Cash/Debt	$25M	$36M
Current Ratio (TTM)	7.98x	7.51x
Quick Ratio (TTM)	7.76x	7.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	1.11
52W Performance	7.7%	-53.6%
YTD Performance	20.3%	-39.2%
% from 52W High	-39.5%	-55.9%
% from 52W Low	32.4%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.14x
FCF Yield (TTM)	-58.3%	-82.0%
Earnings Yield (TTM)	-72.9%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-371.4
EV/GP/RG	N/A	N/A
Ticker research	View NKTX research	View VYGR research

Valuation

P/S Ratio

NKTX

0.00x

VYGR

4.30x

EV/FCF

NKTX

-1.45x

VYGR

-0.92x

Growth & revenue

Revenue Growth TTM

VYGR

-19.1%

Forward Revenue Growth

NKTX

2561.2%

VYGR

129.7%

Profitability & performance

Gross Margin

NKTX

0.0%

VYGR

0.0%

ROE

NKTX

-3964.0%

VYGR

-5792.0%

FCF Yield %

NKTX

-58.3%

VYGR

-82.0%

52-Week Performance

NKTX

7.7%

VYGR

-53.6%

Detailed metrics comparison

NKTX

Nkarta Inc

VYGR

Voyager Therapeutics Inc

Market Cap

NKTX$161M

VYGR$148M

Enterprise Value

NKTX$136M

VYGR$112M

Price

NKTX$2.25

VYGR$2.45

P/E Ratio

NKTXN/A

VYGRN/A

P/S Ratio

NKTX0.00x

VYGR4.30x

EV/Sales

NKTX0.00x

VYGR3.26x

EV/EBITDA

NKTX0.00x

VYGR8.61x

P/B Ratio

NKTX0.74x

VYGR1.01x

P/FCF Ratio

NKTXN/A

VYGRN/A

EV/FCF

NKTX-1.45x

VYGR-0.92x

PEG Ratio

NKTXN/A

VYGRN/A

Forward P/E (NTM)

NKTXN/A

VYGRN/A

Forward P/S (NTM)

NKTXN/A

VYGR5.33x

Revenue (TTM)

NKTX$0

VYGR$34M

Revenue Growth (YoY)

NKTXN/A

VYGR-19.1%

Forward Rev Growth

NKTX2561.2%

VYGR129.7%

Gross Margin (TTM)

NKTX0.0%

VYGR0.0%

Operating Margin (TTM)

NKTX0.0%

VYGR0.0%

EBITDA Margin (TTM)

NKTX0.0%

VYGR-329.0%

Net Margin (TTM)

NKTX0.0%

VYGR-312.6%

FCF Margin (TTM)

NKTXN/A

VYGR-352.4%

Net Income (TTM)

NKTX$-117M

VYGR$-108M

FCF (TTM)

NKTX$-94M

VYGR$-121M

EPS (TTM)

NKTX-$1.57

VYGR-$1.78

ROE (TTM)

NKTX-3964.0%

VYGR-5792.0%

ROA (TTM)

NKTX-3045.0%

VYGR-4500.0%

ROIC (TTM)

NKTX-3964.0%

VYGR-5792.0%

Cash

NKTX$25M

VYGR$36M

Debt

NKTX$0

VYGR$0

Net Cash/Debt

NKTX$25M

VYGR$36M

Current Ratio (TTM)

NKTX7.98x

VYGR7.51x

Quick Ratio (TTM)

NKTX7.76x

VYGR7.16x

Debt/Equity (TTM)

NKTX0.00x

VYGR0.00x

Debt/Assets (TTM)

NKTX0.0%

VYGR0.0%

Interest Coverage (TTM)

NKTXN/A

VYGRN/A

Net Debt/EBITDA (TTM)

NKTX0.00x

VYGR0.00x

Beta

NKTX1.19

VYGR1.11

52W Performance

NKTX7.7%

VYGR-53.6%

YTD Performance

NKTX20.3%

VYGR-39.2%

% from 52W High

NKTX-39.5%

VYGR-55.9%

% from 52W Low

NKTX32.4%

VYGR5.2%

Asset Turnover (TTM)

NKTX0.00x

VYGR0.14x

FCF Yield (TTM)

NKTX-58.3%

VYGR-82.0%

Earnings Yield (TTM)

NKTX-72.9%

VYGR-72.8%

Dividend Yield (TTM)

NKTXN/A

VYGRN/A

Rule of 40

NKTX0.0

VYGR-371.4

EV/GP/RG

NKTXN/A

VYGRN/A

Ticker research

View NKTX research View VYGR research

Metric	NKTX Nkarta Inc	VYGR Voyager Therapeutics Inc
Market & Valuation
Market Cap	$161M	$148M
Enterprise Value	$136M	$112M
Price	$2.25	$2.45
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	4.30x
EV/Sales	0.00x	3.26x
EV/EBITDA	0.00x	8.61x
P/B Ratio	0.74x	1.01x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.45x	-0.92x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	5.33x
Revenue & Growth
Revenue (TTM)	$0	$34M
Revenue Growth (YoY)	N/A	-19.1%
Forward Rev Growth	2561.2%	129.7%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-329.0%
Net Margin (TTM)	0.0%	-312.6%
FCF Margin (TTM)	N/A	-352.4%
Net Income (TTM)	$-117M	$-108M
FCF (TTM)	$-94M	$-121M
EPS (TTM)	-$1.57	-$1.78
ROE (TTM)	-3964.0%	-5792.0%
ROA (TTM)	-3045.0%	-4500.0%
ROIC (TTM)	-3964.0%	-5792.0%
Financial Health
Cash	$25M	$36M
Debt	$0	$0
Net Cash/Debt	$25M	$36M
Current Ratio (TTM)	7.98x	7.51x
Quick Ratio (TTM)	7.76x	7.16x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.19	1.11
52W Performance	7.7%	-53.6%
YTD Performance	20.3%	-39.2%
% from 52W High	-39.5%	-55.9%
% from 52W Low	32.4%	5.2%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.14x
FCF Yield (TTM)	-58.3%	-82.0%
Earnings Yield (TTM)	-72.9%	-72.8%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-371.4
EV/GP/RG	N/A	N/A
Ticker research	View NKTX research	View VYGR research